Oxygen Biotherapeutics said that Dermacyte Oxygen Concentrate is the first product in a cosmetic line which is presently under development. It uses the company’s patented Oxycyte technology, an oxygen carrier scientifically designed to enhance oxygen delivery to tissues such as skin.
According to Oxygen Biotherapeutics, some key advantages of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.
Chris Stern, chairman and CEO of Oxygen Biotherapeutics, said: “Inventory of Dermacyte sold out quickly last fall when it was originally introduced in a market test designed to gauge customer interest and response. The feedback we received from customers was quite positive. We’ve improved the Dermacyte concentrate to be smoother and more effective. Therefore, we believe that our new cosmetic line has the potential to be a significant financial contributor to our company.”
Oxygen Biotherapeutics is focused on commercialization of pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier, liquid ventilation product (Oxycyte) and has out-licensed an implantable glucose sensor. The products are based upon core technologies that include biomedical applications for PFCs, and also medical and industrial applications for biosensors.